Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Late B Cell-Specific Dis3-Knockout Mice Do Not Develop Plasma Cell Neoplasm

Hiroto Ohguchi, Yasuyo Ohguchi, Sho Kubota, Takako Yokomizo-Nakano, Ai Hamashima, Kimi Araki, Goro Sashida

Blood (2023) 142 (Supplement 1): 4658.

https://doi.org/10.1182/blood-2023-173003

Published: 2023

Journal Articles

Proteomic Analysis of Monoclonal Plasma Cells from Plasma Cell Dyscrasias

Yawara Kawano, Takeshi Masuda, Shiho Fujiwara, Junzhe Bai, Nao Nishimura, Hiroto Ohguchi, Jun-ichirou Yasunaga

Blood (2023) 142 (Supplement 1): 4776.

https://doi.org/10.1182/blood-2023-188213

Published: 2023

Journal Articles

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

Daisuke Ogiya, Jiye Liu, Hiroto Ohguchi, Keiji Kurata, Mehmet K. Samur, Yu-Tzu Tai, Sophia Adamia, Kiyoshi Ando, Teru Hideshima, Kenneth C. Anderson

Blood (2020) 136 (20): 2334–2345.

https://doi.org/10.1182/blood.2019004332

Published: 2020

Includes: Supplemental data

Journal Articles

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

Takeshi Harada, MD PhD, Asuka Oda, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Hirofumi Tenshin, DDS, PhD, Masahiro Hiasa, DDS, PhD, Jumpei Teramachi, Masahiro Oura, MD, Kimiko Sogabe, MD, Shiro Fujii, MD PhD, Shingen Nakamura, MD PhD, Hirokazu Miki, MD PhD, Kumiko Kagawa, MD PhD, Shuji Ozaki, MD PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Masahiro Abe, MD PhD

Blood (2019) 134 (Supplement_1): 3111.

https://doi.org/10.1182/blood-2019-127679

Published: 2019

Journal Articles

JAK-STAT3 Pathway Regulates CD38 Expression on Multiple Myeloma Cells

Daisuke Ogiya, MD PhD, Jiye Liu, PhD, Hiroto Ohguchi, MD PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MD PhD, Kenneth Anderson, MD

Blood (2018) 132 (Supplement 1): 4440.

https://doi.org/10.1182/blood-2018-99-112425

Published: 2018

Journal Articles

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

Teru Hideshima, Francesca Cottini, Yoshihisa Nozawa, Hyuk-Soo Seo, Hiroto Ohguchi, Mehmet K. Samur, Diana Cirstea, Naoya Mimura, Yoshikazu Iwasawa, Paul G. Richardson, Nikhil C. Munshi, Dharminder Chauhan, Walter Massefski, Teruhiro Utsugi, Sirano Dhe-Paganon, Kenneth C. Anderson

Blood (2017) 129 (10): 1308–1319.

https://doi.org/10.1182/blood-2016-09-738500

Published: 2017

Includes: Supplemental data

Journal Articles

Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma

Morihiko Sagawa, MD PhD, Hiroto Ohguchi, MD PhD, Takeshi Harada, MD PhD, Mehmet K. Samur, PhD, Yu-Tzu Tai, PhD, Nikhil C Munshi, MD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 360.

https://doi.org/10.1182/blood.V128.22.360.360

Published: 2016

Journal Articles

HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma

Takeshi Harada, MD PhD, Hiroto Ohguchi, MD PhD, Yohann Grondin, PhD, Shohei Kikuchi, MD PhD, Morihiko Sagawa, MD PhD, Yu-Tzu Tai, PhD, Ralph Mazitschek, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD

Blood (2016) 128 (22): 4472.

https://doi.org/10.1182/blood.V128.22.4472.4472

Published: 2016

Journal Articles

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

Blood (2016) 127 (9): 1138–1150.

https://doi.org/10.1182/blood-2015-06-649970

Published: 2016

Includes: Supplemental data

Journal Articles

The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival

Hiroto Ohguchi, MD PhD, Teru Hideshima, MDPhD, Manoj Bhasin, PhD, Gullu Gorgun, PhD, Loredana Santo, MD, Michele Cea, MD, Naoya Mimura, MD PhD, Rikio Suzuki, MDPhD, Yu-Tzu Tai, PhD, Ruben D. Carrasco, MD PhD, Noopur S. Raje, MD, Paul G. Richardson, MD, Hideo Harigae, MD PhD, Takaomi Sanda, MD PhD, Kenneth C. Anderson, MD

Blood (2015) 126 (23): 3633.

https://doi.org/10.1182/blood.V126.23.3633.3633

Published: 2015

Journal Articles

Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma

Gullu Topal Gorgun, PhD, Kristen Cowens, Steven Paula, Mehmet Kemal Samur, PhD, Hiroto Ohguchi, MD PhD, Ahaana Singh, Randie E White, Giada Bianchi, MD, Rikio Suzuki, MDPhD, Shohei Kikuchi, MDPhD, Takeshi Harada, MDPhD, Naoya Mimura, MD PhD, Yu-Tzu Tai, PhD, Teru Hideshima, MDPhD, Jacob P. Laubach, MD, Noopur Raje, MD, Nikhil C. Munshi, MD, Paul G. Richardson, Kenneth C. Anderson

Blood (2014) 124 (21): 27.

https://doi.org/10.1182/blood.V124.21.27.27

Published: 2014

Journal Articles

Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma

Rikio Suzuki, MD, PhD, Teru Hideshima, MD, PhD, Shuichi Ohkubo, PhD, Naoya Mimura, MD, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Shohei Kikuchi, MD, PhD, Diana D. Cirstea, Francesca Cottini, MD, Dharminder Chauhan, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Teruhiro Utsugi, PhD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 4429.

https://doi.org/10.1182/blood.V122.21.4429.4429

Published: 2013

Journal Articles

Inhibition Of Myeloid Derived Suppressor Cells (MDSC) In The Multiple Myeloma Bone Marrow Microenvironment

Gullu Topal Gorgun, PhD, Hiroto Ohguchi, MD, PhD, Teru Hideshima, MD, PhD, Yu-Tzu Tai, PhD, Noopur Raje, MD, Nikhil C. Munshi, MD, Paul G. Richardson, MD, Jacob P. Laubach, MD, Kenneth C. Anderson, MD

Blood (2013) 122 (21): 3089.

https://doi.org/10.1182/blood.V122.21.3089.3089

Published: 2013

Journal Articles

Induction of Thymic Stromal Lymphopoietin in Mesenchymal Stem Cells by Interaction with Myeloma Cells

Shinji Nakajima, MD, PhD, Hiroto Ohguchi, MD, PhD, Yasushi Onishi, MD, PhD, Mayumi Kamata, MD, Tohru Fujiwara, MD, PhD, Yoko Okitsu, MD, PhD, Noriko Fukuhara, MD, PhD, Kenichi Ishizawa, MD, PhD, Hideo Harigae, MD, PhD

Blood (2012) 120 (21): 1825.

https://doi.org/10.1182/blood.V120.21.1825.1825

Published: 2012

Journal Articles

TAS-117, a Novel Selective Akt Inhibitor Demonstrates Significant Growth Inhibition in Multiple Myeloma Cells in Vitro and in Vivo

Naoya Mimura, Hiroto Ohguchi, Diana Cirstea, MD, Francesca Cottini, Gullu Topal Gorgun, PhD, Jiro Minami, Rikio Suzuki, Toshiyasu Shimomura, PhD, Teruhiro Utsugi, PhD, Teru Hideshima, MD, PhD, Kenneth C. Anderson, MD

Blood (2012) 120 (21): 942.

https://doi.org/10.1182/blood.V120.21.942.942

Published: 2012

Journal Articles

Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma

Diana Cirstea, Teru Hideshima, MD, PhD, Loredana Santo, Homare Eda, Tyler A. Scullen, Neeharika Nemani, Anuj Mahindra, Andrew Yee, Yiguo Hu, Naoya Mimura, Jiro Minami, Hiroto Ohguchi, Rikio Suzuki, Francesca Cottini, Sylvie M Guichard, Kenneth C. Anderson, Noopur Raje

Blood (2012) 120 (21): 4023.

https://doi.org/10.1182/blood.V120.21.4023.4023

Published: 2012

Journal Articles

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Blood (2012) 119 (24): 5772–5781.

https://doi.org/10.1182/blood-2011-07-366633

Published: 2012

Includes: Supplemental data

Journal Articles

Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma

Gullu Gorgun, PhD, Teru Hideshima, MD, PhD, Noopur S. Raje, MD, Naoya Mimura, MD, PhD, James E. Bradner, MD, Diana Cirstea, MD, Loredana Santo, MD, Yu-Tzu Tai, PhD, Michael Sellitto, Yiguo Hu, PhD, Claire Fabre, MD, PhD, Hiroto Ohguchi, MD, PhD, Jiro Minami, MD, PhD, Paul G. Richardson, MD, Nikhil C. Munshi, MD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 128.

https://doi.org/10.1182/blood.V118.21.128.128

Published: 2011

Journal Articles

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Blood (2011) 118 (21): 133.

https://doi.org/10.1182/blood.V118.21.133.133

Published: 2011

Journal Articles

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)

Claire Fabre, MD, PhD, Naoya Mimura, MD, PhD, Kathryn Bobb, MS, Gullu Gorgun, PhD, Diana D. Cirstea, MD, Yiguo Hu, PhD, Jiro Minami, MD, PhD, Hiroto Ohguchi, MD, PhD, Jie Zhang, PhD, Jeffrey Meshulam, BS, Constantine S. Mitsiades, MD, PhD, Paul G. Richardson, MD, Teru Hideshima, MD, PhD, Kenneth C. Anderson, MD

Blood (2011) 118 (21): 2902.

https://doi.org/10.1182/blood.V118.21.2902.2902

Published: 2011

NARROW

Late B Cell-Specific Dis3-Knockout Mice Do Not Develop Plasma Cell Neoplasm

Proteomic Analysis of Monoclonal Plasma Cells from Plasma Cell Dyscrasias

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications

Novel Therapeutic Rationale for Targeting HDAC1 and PIM2 in Multiple Myeloma

JAK-STAT3 Pathway Regulates CD38 Expression on Multiple Myeloma Cells

p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma

Targeting Ribonucleotide Reductase M1 and M2 in Multiple Myeloma

HDAC3 Maintains DNMT1 through Dual Mechanisms in Multiple Myeloma

Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells

The KDM3A-KLF2-IRF4 Axis Maintains Myeloma Cell Survival

Targeting Immune Suppressive Microenvironment By Immune Checkpoint Blockade in Multiple Myeloma

Antitumor Activities Of An Oral Selective HSP90α/β Inhibitor, TAS-116, In Combination With Bortezomib In Multiple Myeloma

Inhibition Of Myeloid Derived Suppressor Cells (MDSC) In The Multiple Myeloma Bone Marrow Microenvironment

Induction of Thymic Stromal Lymphopoietin in Mesenchymal Stem Cells by Interaction with Myeloma Cells

TAS-117, a Novel Selective Akt Inhibitor Demonstrates Significant Growth Inhibition in Multiple Myeloma Cells in Vitro and in Vivo

Rational Combination Treatment of a Novel Selective mTOR Kinase Inhibitor AZD8055 with IGF-1R Inhibitors in Multiple Myeloma

Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma

Immunomodulatory Effects of Histone Deacetylase 6 Inhibition in Suppressor Immune Cells in Multiple Myeloma

Blockade of XBP1 Splicing by Inhibition of IRE1α Is a Promising Therapeutic Option in Multiple Myeloma

Dual Inhibition of Canonical and Non-Canonical NF-KB Pathway Demonstrates Significant Anti-Tumor Activities in Multiple Myeloma (MM)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only